|MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies|
MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.
|A Rapid and Effective Tool for Monitoring Monoclonal Antibody Production|
B. Bhullar, Ph.D., Carlina Hui, B.Sc., M. Hariharan, M.Sc., J. Hewitt, B.Sc , and N. Vats, Ph.D.
Monoclonal antibodies (Mab) are used in a variety of fields from diagnostics to therapeutics. Manufacturers of in vitro diagnostics (IVD) commonly use third-party suppliers to meet their needs for specified monoclonal antibodies.
|Comparison of Three Methods for the Evaluation of Cytokine Storm Risk in Early and Clinical Stage Biopharmaceutical Development|
Gary dos Santos and Emer Clarke
Objective: To identify an assay that can accurately predict the risk of CRS and CS associated with investigational biotherapeutics. A comparison of three methods were used: (a) immobilization of test antibody on plastic, (b) co-culture of PBMC's on HUVEC's and (c) pre-culture of PBMC's at high cell density.
|Automated Quantitative Analysis of Ethanol, Glucose and NADH in the UV/VIS and Short NIR|
Process Analytical Technology currently becomes more and more important for food and pharmaceutical industry for example because of the increasing demand for more effective and efficient quality control. Therefore it is necessary to get timely and targeted responses of the different parameters in bioprocesses. To attain this aim, it is helpful to replace the conventional (manual) laboratory techniques with automated measuring processes via in-line probe.
|A Novel Synthetic Peptide as a Tool for Microvesicles / Exosomes isolation ©|
We have engineered and validated a synthetic peptide (Vn96*) with specific affinity for canonical heat shock proteins (HSPs) as a tool for rapid isolation of Exosomes or extracellular microvesicles (together referred to as eMVs here) from cell culture media, human and animal body-fluids.
|Acute Infective Endocarditis: Early Surgery versus Conventional Treatment|
Yassar Abdullah S Alamri
Infective endocarditis (IE) refers to thew inflammation of the inner layer of the heart, the endocardium, secondary to an infectious (most commonly bacterial) agent. It affects the left side of the heart more commonly than the right. IE has an estimated incidence of 1.4 to 6.2 per 10,000 persons in the developed countries, and is most commonly caused by Staphylococcus aureus, coaguase-negative staphylococcus, Viridans group streptococci and Straptococcus bovis.
|First total synthesis of Combretastatin D-2 congeners named Isocorniculatolide A and 11-o-methylisocornicultolide|
Vijaya Kumar.Tulam, Subhash Chandra Bose. Kotte, Sanjay Kumar. Hirasker, Prathama S Mainkar, P.M. Murali and K. Mukkanti.
As a part of our ongoing research in synthesizing the Biologically important Natural Products, here we are reporting First total synthesis of newly isolated isocorniculatolide A and 11-O-methyl corniculatolide A.
|Analyzing Molecular Polar Surface Descriptors to Predict Blood-Brain Barrier Permeation|
Sergey Shityakova, Winfried Neuhausa, Thomas Dandekarc and Carola Förstera
Permeation of active drugs across the vascular brain endothelium into the central nervous system (CNS) is controlled by the blood-brain barrier (BBB). Some molecular quantities like polar surface (PS) descriptors are of key interest to medicinal chemists to predict the BBB permeation fate for different drug-like chemical compounds.
|Automated Solutions for Cellular Screening and Characterization of Therapeutic Antibodies for Antibody-Dependent Cellular Cytotoxicity Utility|
Brad Larson, Peter Banks , Nicolas Pierre, Stéphane Martinez, and Francois Degorce
Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. Here we present the automation of two assays for the characterization and selection of potent antibody drug candidates. Both assays rely on HTRF® detection. The first assay quantifies the binding affinity of antibodies to their target antigen, on live cells.
|<< || 1 2 3 || >>|
|Showing Results 11 - 20 of 28||